Variations in Circulating Active MMP-9 Levels During Renal Replacement Therapy

• Published in: Biomolecules (Basel, Switzerland) Switzerland), 2020-03, Vol.10 (4), p.505
• Main Authors: Rodríguez-Sánchez, Elena, Navarro-García, José Alberto, Aceves-Ripoll, Jennifer, Abarca-Zabalía, Judith, Susmozas-Sánchez, Andrea, Bada-Bosch, Teresa, Hernández, Eduardo, Mérida-Herrero, Evangelina, Andrés, Amado, Praga, Manuel, Fernández-Ruiz, Mario, Aguado, José María, Segura, Julián, Ruilope, Luis Miguel, Ruiz-Hurtado, Gema
• Format: Article
• Language: English
• Subjects: Adult; Aged; Blood Pressure; Creatinine; Dialysis; Dialysis (Chemical process); Female; Gelatinase B; Hemodiafiltration; high-flux dialysis; Humans; Hypertension; Inflammation; Kidney diseases; Kidney Transplantation; Kidney transplants; Male; Matrix metalloproteinase; Matrix Metalloproteinase 9 - blood; Matrix metalloproteinase inhibitors; matrix metalloproteinase-9; Measurement; Metalloproteinase; Methods; Middle Aged; on-line hemodiafiltration; Oxidative stress; Patient outcomes; Patients; Peritoneal dialysis; Renal Dialysis; Renal function; Renal Replacement Therapy; Tissue Inhibitor of Metalloproteinase-1 - blood; Transplants & implants; Varieties; Vascular Stiffness
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom10040505

Renal replacement therapy (RRT) is complicated by a chronic state of inflammation and a high mortality risk. However, different RRT modalities can have a selective impact on markers of inflammation and oxidative stress. We evaluated the levels of active matrix metalloproteinase (MMP)-9 in patients undergoing two types of dialysis (high-flux dialysis (HFD) and on-line hemodiafiltration (OL-HDF)) and in kidney transplantation (KT) recipients. Active MMP-9 was measured by zymography and ELISA before (pre-) and after (post-) one dialysis session, and at baseline and follow-up (7 and 14 days, and 1, 3, 6, and 12 months) after KT. Active MMP-9 decreased post-dialysis only in HFD patients, while the levels in OL-HDF patients were already lower before dialysis. Active MMP-9 increased at 7 and 14 days post-KT and was restored to baseline levels three months post-KT, coinciding with an improvement in renal function and plasma creatinine. Active MMP-9 correlated with pulse pressure as an indicator of arterial stiffness both in dialysis patients and KT recipients. In conclusion, active MMP-9 is better controlled in OL-HDF than in HFD and is restored to baseline levels along with stabilization of renal parameters after KT. Active MMP-9 might act as a biomarker of arterial stiffness in RRT.